OTC · PKANF
Simply Better Brands Corp.
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
Loading market information…
OTC · MRVFF · USD
Stock price, earnings
Quote as of Mar 13, 2023, 07:42 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nuvo Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nuvo Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nuvo Pharmaceuticals Inc., which operates globally under the trade name Miravo Healthcare, specializes in delivering both prescription and over-the-counter medical products. The company's diverse portfolio addresses key therapeutic areas, including pain management, allergy relief, neurological conditions, and dermatological concerns. Its operations are structured into three distinct business units: a Commercial division, a Production and Service division, and a Licensing and Royalty division. Among its significant offerings are Blexten, an antihistamine prescribed for the symptomatic treatment of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine episodes; and Suvexx/Treximet, another medication for migraine. Nuvo also provides NeoVisc, an injectable viscosupplement utilized in managing osteoarthritis, alongside treatments for head lice infestations such as Resultz, FullMarks, and LAUSBUB. For metabolic health, the company supplies Bezalip SR, aimed at patients with elevated cholesterol or triglyceride levels, and Proferrin, an iron supplement for the prevention and treatment of iron deficiency. Their pain relief options include Fiorinal 1 and Fiorinal C1 for tension-type headaches, and Collatamp G, designed for surgical implantation during operations. Nuvo's gastrointestinal product line features PegaLAX, a laxative for occasional constipation; Mutaflor, a probiotic to manage chronic constipation, abdominal pain, and cramps; and MoviPrep, used for bowel cleansing in preparation for colonoscopies. Soriatane is available for the treatment of psoriasis and other keratinization disorders. Additionally, their range of topical solutions includes Pennsaid and Pennsaid 2% for osteoarthritic pain; Vimovo, which alleviates arthritis symptoms; SYNERA and RAPYDAN topical patches, employed to mitigate pain during needle sticks and other superficial skin procedures; and the Heated Lidocaine/Tetracaine Patch, applied prior to painful medical interventions. Yosprala is also part of their portfolio, focused on preventing heart attacks and strokes. The company was originally incorporated in 1983 and was formerly known as Nuvo Research Inc. It officially adopted the name Nuvo Pharmaceuticals Inc. in March 2016 and maintains its corporate headquarters in Mississauga, Canada.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 14, 2019 |
| -$0.52-85.71% vs estimate |
| $0.00 |
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
KEEP COMPARING
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
$0.27+$0.01 (+2.88%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 94.75% below the high.
$0.22-$0.00 (-0.19%)
Antibe Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.19% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
